Michael Chorny

faculty photo
Research Associate Professor of Pediatrics
Member, Institute of Translational Medicine and Therapeutics at the University of Pennsylvania
Associate Director, Center for Targeted Therapeutics & Translational Nanomedicine of the ITMAT (Institute of Translational Medicine & Therapeutics)
Member, Penn Medicine Cardiovascular Institute at the University of Pennsylvania
Member, Center for Childhood Cancer Research, The Children’s Hospital of Philadelphia Research Institute
Associate Member, Pediatric Oncology Program at the Abramson Cancer Center of the University of Pennsylvania
Department: Pediatrics

Contact information
The Abramson Pediatric Research Center, Suite 702G
The Children's Hospital of Philadelphia
3615 Civic Center Blvd.
Philadelphia, PA 19104
Office: 215-590-3063
Education:
BPharm (Pharmaceutical sciences)
The Hebrew University of Jerusalem, Israel, 1996.
MS (Pharmaceutical sciences)
The Hebrew University of Jerusalem, Israel, 1997.
PhD (Pharmaceutical sciences)
The Hebrew University of Jerusalem, Israel, 2004.
Permanent link
 

Description of Itmat Expertise

Design of drug, gene, protein and cell delivery systems
Magnetically targeted therapy of arterial restenosis
Nanocarrier-based site-specific gene delivery methods
Prodrug and codrug design
Nanocarrier/prodrug combinations for treating solid tumors

Description of Research Expertise

delivery systems; biodegradable nanocarriers; magnetic targeting of small molecule drugs and biotherapeutics; prodrug and codrug design; targeted therapy of proliferative diseases, arterial restenosis and pediatric solid tumors; neuroblastoma

Selected Publications

M.R. Battig, I.S. Alferiev, D.T. Guerrero, I. Fishbein, B.B. Pressly, R.J. Levy, M. Chorny: Experimental Single-Platform Approach to Enhance the Functionalization of Magnetically Targetable Cells. ACS Appl Bio Mater 3(6): 3914-3922, May 2020.

W. Shield III, A. Cellini, H. Tian , K. Wilson, Y. Dan, J.M. Abzug, S. Garcia, N. Moritani, I. Alferiev, M. Chorny, M. Takigawa, V.Y. Ng, M. Iwamoto, M. Enomoto-Iwamoto: Selective agonists for nuclear retinoic acid receptor gamma inhibit growth of HCS-2/8 chondrosarcoma cells. Journal of Orthopaedic Research 38(5): 1045-1051, May 2020.

I. Orienti, F. Nguyen, P. Guan, V. Kolla, N. Calonghi, G. Farruggia, M. Chorny, G.M. Brodeur: A novel nanomicellar combination of fenretinide and lenalidomide shows marked antitumor activity in a neuroblastoma xenograft model. Drug Design, Development and Therapy 13: 4305-4319, Dec 2019.

M.R. Battig, I. Fishbein, R.J. Levy, I.S. Alferiev, D. Guerrero, M. Chorny: Optimizing endothelial cell functionalization for cell therapy of vascular proliferative disease using a direct contact co-culture system. Drug Delivery and Translational Research 8(4): 954-963, Aug 2018.

F. Nguyen, I. Alferiev, P. Guan, D.T. Guerrero, V. Kolla, G.S. Moorthy, M. Chorny*, G.M. Brodeur*: Enhanced intratumoral delivery of SN38 as a tocopherol oxyacetate prodrug using nanoparticles in a neuroblastoma xenograft model. Clinical Cancer Research 24(11): 2585-2593, Jun 2018 Notes: (* equal contribution).

I. Fishbein, D. Guerrero, I.S. Alferiev, J. Foster, N. Minutolo, M. Chorny, A.M. Monteys, K.H. Driesbaugh, C. Nagaswami, R.J. Levy: Stent-based delivery of adeno-associated viral vectors with sustained vascular transduction and iNOS-mediated inhibition of in-stent restenosis. Gene Therapy 24(11): 717-726, Nov 2017.

I. Fishbein, T. Welch, D.T. Guerrero, I.S. Alferiev, R.F. Adamo, M. Chorny, R.K. Gupte, Y. Tang, R.J. Levy: Paraffin processing of stented arteries using a postfixation dissolution of metallic and polymeric stents. Cardiovascular Patholology 25(6): 483-88, Sep 2016.

R.F. Adamo, I. Fishbein, K. Zhang, J. Wen, R.J. Levy, I.S. Alferiev, M. Chorny: Magnetically enhanced cell delivery for accelerating recovery of the endothelium in injured arteries. Journal of Controlled Release 222: 169-75, Jan 2016.

R. Iyer*, J.L. Croucher*, M. Chorny*, J.L. Mangino, I.S. Alferiev, R.J. Levy, V. Kolla, G.M. Brodeur: Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma. Cancer Letters 360(2): 205-12, May 2015 Notes: (* equal contribution).

I.S. Alferiev, R. Iyer, J.L. Croucher, R.F. Adamo, K. Zhang, J.L. Mangino, V. Kolla, I. Fishbein, G.M. Brodeur, R.J. Levy, M. Chorny: Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. Biomaterials 51: 22-9, May 2015.

back to top
Last updated: 07/31/2020
The Trustees of the University of Pennsylvania